Compare Fiverr International Ltd (FVRR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Viatris Inc — how do they compare? Fiverr International Ltd trades at $8.59 (market cap $310.61M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 64.5× Fiverr International Ltd's market cap, and Viatris Inc pays a 2.75% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Viatris Inc for 57 Days on average.
| FVRR | VTRS | |
|---|---|---|
Market Cap | $310.61M | $20.03B |
Volume | 381,459 | 14,109,977 |
Sector | Media | Health |
52-Week High | $23.60 | $18.27 |
52-Week Low | $8.47 | $9.74 |
Typical Hold Time | 62 Days | 57 Days |
Enterprise Value | $63.00M | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.68, up 2.12% with bearish technical signals despite attractive valuation metrics including a P/E of 10.67 and P/S of 0.76. Recent earnings show mixed results with Q2 2026 missing estimates, while revenue growth has slowed from 2025's $431M to projected $418M in 2026. The company faces AI disruption pressures but maintains strong gross margins of 82% and positive net income.
The outlook remains cautious with analysts predominantly holding neutral ratings (76% Hold) and a $10.50 price target suggesting modest upside. Key risks include AI competition compressing freelance demand, while potential exists if Fiverr successfully adapts its platform to AI-driven market changes. Current valuation appears reasonable for patient investors despite near-term headwinds.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
